Price T Rowe Associates Inc Century Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 14,882 shares of IPSC stock, worth $8,333. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,882
Previous 14,882
-0.0%
Holding current value
$8,333
Previous $16,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding IPSC
# of Institutions
69Shares Held
26.9MCall Options Held
12.1KPut Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$3.03 Million0.87% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$1.8 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.62 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.5MShares$1.4 Million0.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.38MShares$1.33 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $33M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...